Endogenous glucagon-like peptide-1 system response is impaired during ST-elevation myocardial infarction in type 2 diabetes patients

Abstract Background To analyze incidence, use of therapeutic procedures, and in-hospital outcomes in patients with ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) according to the presence of type 2 diabetes (T2DM) in Spain (2016–2018) and to investigate sex differences. Methods Using the Spanish National Hospital Discharge Database, we estimated the incidence of myocardial infarctions (MI) in men and women with and without T2DM aged ≥ 40 years. We analyzed comorbidity, procedures, and outcomes. We matched each man and woman with T2DM with a non-T2DM man and woman of identical age, MI code, and year of hospitalization. Propensity score matching was used to compare men and women with T2DM. Results MI was coded in 109,759 men and 44,589 women (30.47% with T2DM). The adjusted incidence of STEMI (IRR 2.32; 95% CI 2.28–2.36) and NSTEMI (IRR 2.91; 95% CI 2.88–2.94) was higher in T2DM than non-T2DM patients, with higher IRRs for NSTEMI in both sexes. The incidence of STEMI and NSTEMI was higher in men with T2DM than in women with T2DM. After matching, percutaneous coronary intervention (PCI) was less frequent among T2DM men than non-T2DM men who had STEMI and NSTEMI. Women with T2DM and STEMI less frequently had a code for PCI that matched that of non-T2DM women. In-hospital mortality (IHM) was higher among T2DM women with STEMI and NSTEMI than in matched non-T2DM women. In men, IHM was higher only for NSTEMI. Propensity score matching showed higher use of PCI and coronary artery bypass graft and lower IHM among men with T2DM than women with T2DM for both STEMI and NSTEMI. Conclusions T2DM is associated with a higher incidence of STEMI and NSTEMI in both sexes. Men with T2DM had higher incidence rates of STEMI and NSTEMI than women with T2DM. Having T2DM increased the risk of IHM after STEMI and NSTEMI among women and among men only for NSTEMI. PCI appears to be less frequently used in T2DM patients After STEMI and NSTEMI, women with T2DM less frequently undergo revascularization procedures and have a higher mortality risk than T2DM men.

Download Full-text

Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2015-3291 ◽

2016 ◽

Vol 101 (5) ◽

pp. 2122-2129 ◽

Cited By ~ 17

Author(s):

Jennifer S. ten Kulve ◽

Liselotte van Bloemendaal ◽

Rawien Balesar ◽

Richard G. IJzerman ◽

Dick F. Swaab ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Expression ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Diabetes Patients

Download Full-text

1,5-Anhydroglucitol in type 2 diabetes mellitus patients with ST elevation myocardial infarction.

Journal of Clinical Medicine of Kazakhstan ◽

10.23950/jcmk/11042 ◽

2021 ◽

Vol 18 (4) ◽

pp. 52-57

Author(s):

Dinara Sheryazdanova ◽

Yelena Laryushina

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

St Elevation Myocardial Infarction ◽

St Elevation

Download Full-text

IMPACT OF TYPE 2 DIABETES IN NON ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI).

International Journal of Advanced Research ◽

10.21474/ijar01/8231 ◽

2018 ◽

Vol 6 (12) ◽

pp. 1029-1033

Author(s):

Sanoussi Hamza ◽

◽

Hasni MohammedAli ◽

Kourireche Najla ◽

Lakhal Zouhair ◽

...

Keyword(s):

Myocardial Infarction ◽

Type 2 Diabetes ◽

St Elevation Myocardial Infarction ◽

St Elevation

Download Full-text

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology ◽

10.3389/fphar.2021.759262 ◽

2021 ◽

Vol 12 ◽

Author(s):

Chuanjun Zhuo ◽

Chongguang Lin ◽

Chunhua Zhou ◽

Xiangyang Gao ◽

Hailin Shao ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Type 2 Diabetes ◽

Thyroid Carcinoma ◽

Kidney Function ◽

Cardiovascular Outcome Trials ◽

Secondary Outcomes ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was conducted. Randomized controlled cardiovascular outcome trials of type 2 diabetes mellitus (T2DM) patients administered GLP-1 RAs were included. The following primary outcomes were examined: cardiovascular death, major adverse cardiovascular events (MACE), myocardial infarction, stroke, mortality, heart failure, hypoglycemia, pancreatitis, and thyroid carcinoma. Secondary outcomes included: composite kidney outcome, worsening kidney function, macroalbuminuria, and retinopathy.Results: Seven trials involving 56,004 patients and eight interventions were identified. Albiglutide was associated with fewer MACE and myocardial infarction events compared with lixisenatide. Lixisenatide was related to a greater number of stroke events and cardiovascular deaths compared to once-weekly semaglutide and oral semaglutide, respectively. Improved mortality was associated with oral semaglutide compared with once-weekly semaglutide, albiglutide, dulaglutide, exenatide, or lixisenatide. Risks of heart failure, thyroid carcinoma, and pancreatitis were similar among all the treatments. Weighting of the nine primary outcomes identified oral semaglutide as first among the eight treatments examined. Among three of the secondary outcomes, once-weekly semaglutide ranked first. Better composite kidney outcome was observed with once-weekly semaglutide than with dulaglutide or exenatide; once-weekly semaglutide improved macroalbuminuria compared with exenatide or lixisenatide; and albiglutide, exenatide, and placebo was associated with fewer cases of retinopathy compared with once-weekly semaglutide. Meanwhile, kidney function was less likely to worsen with dulaglutide than with lixisenatide or placebo.Conclusion: Semaglutide should be considered when GLP-1 RAs are indicated for T2DM patients.

Download Full-text